New Harbor Capital has acquired Monroe Biomedical Research to build out a more robust clinical research platform.
Monroe Biomedical Research is a 6,300-square-foot clinical research facility in Monroe, near Charlotte, North Carolina. Monroe Biomedical conducts clinical research studies for asthma, COPD, diabetes, hypertension, heart failure, Alzheimer’s and COVID-19.
New Harbor Capital invests in lower middle market, growth-oriented business services, healthcare and education companies. Since 2000, New Harbor has completed more than 230 investments.
Crosstree Capital Partners acted as advisor to Monroe Biomedical and helped the target identify New Harbor Capital as the ideal transaction partner. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition marks the 27th clinical trials transaction of the year. This is an increase from last year, when there were 20 clinical trials transactions announced between January 1, 2022, and September 21, 2022.
